Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.
Laboratory of Experimental Cardiology, Federal State Budgetary Scientific Institution, Research Institute for Cardiology, Tomsk, Russia.
Cardiovasc Ther. 2018 Jun;36(3):e12328. doi: 10.1111/1755-5922.12328. Epub 2018 Apr 19.
Adenosine is a breakdown product of adenosine triphosphate and plays an important role in pharmacological preconditioning. The cardioprotective effects of adenosine preconditioning are well established. However, the possible mechanisms need to be explored.
This study was aimed to investigate the possible mechanisms involved in adenosine preconditioning-induced cardioprotection in rats.
Rat heart was isolated and perfused on Langendorff apparatus. Global ischemia for 30 minutes followed by reperfusion for 120 minutes was employed to produce myocardial injury. Myocardial injury was assessed by measuring myocardial infarct size, release of lactate dehydrogenase (LDH) and creatine kinase (CK) in the coronary effluent and hemodynamic parameters including left ventricular developed pressure (LVDP), dp/dt and dp/dt . Serum nitrite levels were measured as an index of nitric oxide release in blood.
Adenosine (4 mg/kg) preconditioning significantly decreased ischemia-reperfusion-induced increase in LDH, CK release, infarct size, improved LVDP, dp/dt and dp/dt and increased serum nitrite levels. Pretreatment with L-NAME, a specific NOS inhibitor, (5 mg/kg) and montelukast, leukotriene receptor antagonist, (10 mg/kg) significantly abrogated the cardioprotective effect of adenosine preconditioning. However, seratrodast, thromboxane A antagonist, (15 mg/kg) had no effect on adenosine-induced cardioprotection. Sodium nitroprusside (SNP) preconditioning also produced cardioprotective effects. However, caffeine (20 mg/kg) (adenosine receptor blocker) and seratrodast (15 mg/kg) had no effect on SNP-induced cardioprotection. Administration of montelukast abrogated the cardioprotective effects of SNP preconditioning-induced cardioprotection.
Adenosine preconditioning may increase the release of nitric oxide, which in turn may increase the release of cysteinyl leukotrienes to confer cardioprotection.
腺苷是三磷酸腺苷的分解产物,在药理学预处理中起着重要作用。腺苷预处理的心脏保护作用已得到充分证实。然而,需要探索其可能的机制。
本研究旨在探讨腺苷预处理诱导大鼠心脏保护作用的可能机制。
采用 Langendorff 装置分离和灌流大鼠心脏。采用 30 分钟整体缺血后再灌注 120 分钟的方法制备心肌损伤模型。通过测量心肌梗死面积、冠状流出液中乳酸脱氢酶(LDH)和肌酸激酶(CK)的释放以及左心室发展压(LVDP)、dp/dt 和 dp/dt 等血流动力学参数来评估心肌损伤。血清中亚硝酸盐水平作为血液中一氧化氮释放的指标进行测量。
腺苷(4mg/kg)预处理可显著降低缺血再灌注引起的 LDH、CK 释放、梗死面积的增加,改善 LVDP、dp/dt 和 dp/dt ,并增加血清中亚硝酸盐水平。预先给予 L-NAME(5mg/kg),一种特异性一氧化氮合酶抑制剂,和孟鲁司特(10mg/kg),白三烯受体拮抗剂,可显著阻断腺苷预处理的心脏保护作用。然而,塞曲司特(15mg/kg),血栓素 A 拮抗剂,对腺苷诱导的心脏保护作用没有影响。硝普钠(SNP)预处理也产生了心脏保护作用。然而,咖啡因(20mg/kg)(腺苷受体阻滞剂)和塞曲司特(15mg/kg)对 SNP 诱导的心脏保护作用没有影响。给予孟鲁司特可阻断 SNP 预处理诱导的心脏保护作用。
腺苷预处理可能增加一氧化氮的释放,进而增加半胱氨酰白三烯的释放,从而发挥心脏保护作用。